Active Implants Corporation Release: FDA Has Granted Investigational Device Exemption (IDE) Approval To Conduct A Pivotal Clinical Trial Of The Nusurface® Meniscus Implant For Early Knee Osteoarthritis
MEMPHIS, Tenn.--(BUSINESS WIRE)--Active Implants, the technology leader in cushion-bearing orthopedics for treatment of osteoarthritis, today announced it has received Investigational Device Exemption (IDE) approval to conduct a pivotal clinical trial of the NUsurface® Meniscus Implant in patients with knee osteoarthritis.
Help employers find you! Check out all the jobs and post your resume.